The DOI matches its Crossref record.
Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease
Abstract
The manufacturer of deprenyl (selegeline; Eldepryl) (Somerset Pharmaceuticals, Tampa, FL) recently advised physicians to avoid prescribing the drug in combination with an antidepressant because of potentially serious CNS toxicity that may represent the serotonin syndrome. Manifestations of the serotonin syndrome vary but may include changes in mental status and motor and autonomic function. To better estimate the frequency of the serotonin syndrome in patients with Parkinson's disease (PD) treated with deprenyl and an antidepressant, we surveyed all investigators in the Parkinson Study Group. Based on estimates provided by the 47 investigators (75%) who responded, 4,568 patients were treated with the combination of deprenyl and an antidepressant medication. Eleven patients (0.24%) were reported to have experienced symptoms possibly consistent with the serotonin syndrome. Only two patients (0.04%) experienced symptoms considered to be serious. No deaths were reported. We also reviewed all published case reports and adverse experiences reported to the U.S. Food and Drug Administration and the manufacturer of Eldepryl. Available information indicates that serious adverse experiences resulting from the combined use of deprenyl and an antidepressant medication in patients with PD are quite rare and that the frequency of the true "serotonin syndrome" is even rarer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810153391607 · Cited by 1,201
Seppi, K., Weintraub, D., Coelho, M., Perez‐Lloret, S., Fox, S. H., Katzenschlager, R., Hametner, E., Poewe, W., Rascol, O., Goetz, C. G., et al. (2011) · Movement Disorders · doi:10.1002/mds.23884 · Cited by 1,141
Depression and Parkinson’s Disease: Current Knowledge
Marsh, L. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0409-5 · Cited by 404
Prevalence, etiology, and treatment of depression in Parkinson’s disease
McDonald, W. M., Richard, I. H., & DeLong, M. R. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00530-4 · Cited by 357
Self-citationComorbidity of depression with other medical diseases in the elderly
Krishnan, K. R. R., Delong, M., Kraemer, H., Carney, R., Spiegel, D., Gordon, C., McDonald, W., Dew, M. A., Alexopoulos, G., Buckwalter, K., et al. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01472-5 · Cited by 290
Metadata
- Authors
- Richard, I. H., Kurlan, R., Tanner, C., Factor, S., Hubble, J., Suchowersky, O., Waters, C., & the Parkinson Study Group
- Venue
- Neurology
- Published
- 1997-04
- Volume
- 48
- Issue
- 4
- Pages
- 1070-1076
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2073991388
- Cited by
- 230
- References
- 0
- FWCI
- 6.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. https://app.cochat.ai/papers/10.1212/wnl.48.4.1070
- The paper
- Richard, I. H., Kurlan, R., Tanner, C., Factor, S., Hubble, J., Suchowersky, O., Waters, C., & the Parkinson Study Group. (1997). Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Neurology. https://doi.org/10.1212/wnl.48.4.1070
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.